Project Grant R44AI122360

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $249,276 to the University of San Francisco (USF) to assess the real-world effectiveness of maternal respiratory syncytial virus (RSV) vaccination. RSV is a leading cause of lower respiratory tract infections in infants, contributing to 33 million episodes and 101,400 deaths globally each year. The project aims to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $741,917 to West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key objectives are to characterize the mechanism of action of a lead antibody candidate, formulate it into a multivalent...

This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the development of monoclonal antibody (mAb) treatments for paramyxovirus infections. The key objectives are to: 1) Define the human B cell repertoire and neutralizing mAbs targeting the parainfluenza virus (PIV) fusion and hemagglutinin-neuraminidase surface proteins; 2) Determine...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,420,190 to the University of California, Davis to understand the reservoir effects and curative potential of a CD3/CCR5 bispecific antibody in infant macaques. The goal is to investigate the ability of this promising antibody, when given soon after antiretroviral therapy (ART) initiation, to safely deplete the SIV...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $232,415.00 to the University of California, Davis to investigate the use of a monoclonal antibody targeting the cytomegalovirus (CMV)-encoded IL-10 protein as a prophylactic treatment to prevent primary CMV infection. The goal is to develop a novel approach to preventing congenital CMV disease, which currently lacks...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,927 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop and characterize broadly neutralizing human monoclonal antibodies (mAbs) as potential therapeutics to inhibit human cytomegalovirus (CMV) infection and dissemination. The key objectives of this 1-year project are to: 1) identify neutralizing CMV mAbs targeting...

The National Institute of Child Health and Human Development (NICHD) awarded a $2,146,691 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to study the effects of the prenatal RSV prefusion F protein-based (RSVpref) vaccine on neonatal, lactation, and child health outcomes. The study will use electronic health record data and state immunization information across four large health systems to evaluate potential impacts on preterm birth,...

This Project Grant award of $565,834 from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the long-term impact of early-life respiratory syncytial virus (RSV) infection on the development of childhood asthma. The research will focus on understanding how RSV infection can cause epigenetic modifications in lung epithelial cells that lead to persistent changes in the lung's...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop broadly neutralizing human monoclonal antibodies (bnAbs) against henipaviruses, a highly pathogenic group of viruses that pose a significant public health concern. The $809,614 award to the Icahn School of Medicine at Mount Sinai will fund a 5-year project to characterize existing bnAbs, design improved...

This Project Grant award from the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research) provides $2,058,402 to The Regents of the University of California, San Francisco (UCSF) to adapt and evaluate a community-based intervention to increase respiratory syncytial virus (RSV) vaccine uptake among Latino older adults. The study aims to leverage UCSF's community partnership to adapt two intervention components - community health...